Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to…
01 May 2026
Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
Buoyed by yet another strong quarter fuelled by obesity drug demand, Eli Lilly has raised its sales expectations for the year ahead. Revenue for Lilly in Q1 2026 reached $19.8bn,…
01 May 2026
BMS brings the buzz around late-stage readouts amid a so-so Q1
The prospect of upcoming pivotal readouts from Bristol Myers Squibb (BMS) has brought a buzz amongst investors, as the company looks to usher in the next generation of “blockbuster-potential” medicines…
01 May 2026
LEO Pharma to acquire gene therapy company Replay
LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for rare genetic dermatological conditions. The acquisition aims to strengthen LEO…
30 Apr 2026
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi has conducted the largest acquisition in its 90-year history, agreeing to buy KalVista Pharmaceuticals in a deal worth around $1.9bn. The Italian pharma company will buy KalVista for $27…
30 Apr 2026
Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy
Teva Pharmaceuticals will acquire neuroscience specialist, Emalex – a move which Teva executive, Evan Lippman, says effectively complements the company’s wider “pivot to growth” strategy. Through this agreement, which will…
30 Apr 2026
Ray Therapeutics receives EMA PRIME status for gene therapy
Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to treat retinitis pigmentosa (RP). The designation recognises the potential of…